Efficacy and safety of ascending dosages of moxidectin and moxidectin-albendazole against Trichuristrichiura in adolescents: a randomized controlled trial.
Preventive chemotherapy is the main strategy to control soil-transmitted helminth (STH) infections. Albendazole and Mebendazole are ubiquitously used but they are not sufficiently effective against Trichuristrichiura. Moxidectin might be a useful addition to the small drug armamentarium. However, the optimal dosage of moxidectin alone and in combination with albendazole against T. trichiura and other STHs has not yet been determined. A phase two, randomized, placebo-controlled, dose-finding trial was conducted in two secondary schools on Pemba Island, Tanzania. Using a computer generated list T. trichiura infected adolescents were randomly assigned to 7 treatment arms: 8, 16 or 24 mg moxidectin monotherapy or 8, 16, 24 mg moxidectin plus 400 mg albendazole combination therapy or placebo. The primary outcome was cure rate (CR) against T. trichiura analyzed by quadruple Kato-Katz thick smears, 13 to 20 days after treatment. A total of 290 adolescents were enrolled (41 or 42 per arm). CRs against T. trichiura were 43, 46, 44% for 8, 16 and 24 mg of moxidectin alone and 60, 62 and 66% for the same moxidectin dosages plus 400 mg of albendazole, and 12% for placebo. The moxidectin-albendazole arms also revealed higher CRs and egg reduction rates against hookworm than the monotherapy arms. Moxidectin and its combination with albendazole were well tolerated. Moxidectin-albendazole is superior to moxidectin. There is no benefit of increasing the moxidectin dose. The moxidectin-albendazole combination of 8 mg plus 400 mg should be investigated further to develop recommendations for appropriate control of STH infections. Trial Registration: The trial is registered at clinicaltrial.gov, number NCT03501251.